Bingfan Du
Publications by Year
Research Areas
Radiopharmaceutical Chemistry and Applications, HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research, Chemical Synthesis and Analysis, Peptidase Inhibition and Analysis
Most-Cited Works
- → Identification of a Potent, State-Dependent Inhibitor of Nav1.7 with Oral Efficacy in the Formalin Model of Persistent Pain(2011)54 cited
- → Discovery of N-(4-(3-(2-Aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), A Highly Selective, Orally Bioavailable Inhibitor of Aurora Kinases with Activity against Multidrug-Resistant Cancer Cell Lines(2015)44 cited
- → Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target Engagement(2016)37 cited
- → Antifungal activity of a series of 1,2-benzisothiazol-3(2H)-one derivatives(2011)36 cited
- → Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer(2023)35 cited
- → Synthesis of 4-Substituted Chlorophthalazines, Dihydrobenzoazepinediones, 2-Pyrazolylbenzoic Acid, and 2-Pyrazolylbenzohydrazide via 3-Substituted 3-Hydroxyisoindolin-1-ones(2012)34 cited
- → Discovery and hit-to-lead optimization of pyrrolopyrimidines as potent, state-dependent Nav1.7 antagonists(2012)27 cited
- → Abstract 3503: XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab(2022)24 cited
- → The discovery of benzoxazine sulfonamide inhibitors of NaV1.7: Tools that bridge efficacy and target engagement(2017)21 cited
- → Discovery and optimization of aminopyrimidinones as potent and state-dependent Nav1.7 antagonists(2011)18 cited